Wall Street Zen upgraded shares of Werewolf Therapeutics (NASDAQ:HOWL – Free Report) from a sell rating to a hold rating in a research report sent to investors on Saturday morning.
Separately, Weiss Ratings lowered Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 16th. Two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Werewolf Therapeutics presently has a consensus rating of “Hold” and an average price target of $4.00.
Read Our Latest Research Report on HOWL
Werewolf Therapeutics Price Performance
Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last issued its quarterly earnings data on Friday, July 31st. The company reported $0.08 EPS for the quarter, topping the consensus estimate of ($0.28) by $0.36. The company had revenue of $21.00 million during the quarter, compared to analysts’ expectations of $21.00 million. Research analysts anticipate that Werewolf Therapeutics will post -1.08 earnings per share for the current year.
Insider Buying and Selling
In other news, Director Luke Evnin sold 107,429 shares of the stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $0.31, for a total value of $33,302.99. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Ra Capital Management, L.P. sold 416,911 shares of the stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $0.35, for a total value of $145,918.85. Following the completion of the sale, the insider directly owned 303,719 shares in the company, valued at approximately $106,301.65. This represents a 57.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 2,150,574 shares of company stock valued at $819,315. 23.60% of the stock is owned by corporate insiders.
Institutional Trading of Werewolf Therapeutics
Several institutional investors have recently bought and sold shares of the company. Jane Street Group LLC purchased a new position in Werewolf Therapeutics in the 2nd quarter worth approximately $409,000. Bank of America Corp DE bought a new position in Werewolf Therapeutics in the 2nd quarter valued at approximately $112,000. Renaissance Technologies LLC boosted its stake in Werewolf Therapeutics by 48.6% during the 4th quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock valued at $429,000 after purchasing an additional 221,766 shares during the last quarter. Citadel Advisors LLC bought a new stake in shares of Werewolf Therapeutics in the 3rd quarter worth $304,000. Finally, Vanguard Group Inc. increased its holdings in shares of Werewolf Therapeutics by 8.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after purchasing an additional 109,796 shares in the last quarter. 64.84% of the stock is owned by hedge funds and other institutional investors.
About Werewolf Therapeutics
Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.
Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.
Featured Articles
- Five stocks we like better than Werewolf Therapeutics
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
